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MetabolismAbstract The effect of CoO nanoparticles (NPs) on the brain of mice administered through gas-
trointestinal tract for a period of 30 days was studied. AAS analysis revealed that NPs administered
orally were retained by cerebellum, cerebral cortex, medulla oblongata and olfactory bulb. This
retention of nanoparticles by the brain promoted a significant increase in glucose, pyruvate, lactate
and glycogen levels along with the concomitant increase in hexokinase, glucose 6 phosphatase, and
lactate dehydrogense activities. However, a decrease in glucose 6 phosphate dehydrogenase activity
was observed in the brain regions indicating a deterioration of the pentose phosphate pathway.
Thus, the present study suggests that the CoO NPs affect the carbohydrate metabolism of the brain.
 2016 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cobalt is an important metal, which is used as a binder in the
metal industry and as a constituent of most alloys (Jensen
and Tu¨chsen, 1990). Cobalt-based NPs, particularly cobalt
oxide NPs are attracting enormous interest currently due to
their unique shape and size-dependent properties and are
used in different applications like catalysis, magnetism, sen-
sors, electrochemistry, pigments, and energy storage (Liu
et al., 2005; Papis et al., 2009). They are one of the interesting
chemical compounds used in biomedical applications as a
starting material for the construction of dextran coating
and magnetic polymer microspheres. In medicine, cobalt isknown as an MRI contrast agent in combination with iron,
gold, graphite and platinum (Rebello et al., 2010; Magaye
et al., 2012).
Cobalt is also used for anaerobic waste water treatment and
cancer therapy. Exposure of cobalt to humans occurs mainly
from the environment, industry or after joint replacement in
implants from the cobalt-chrome alloy. These exposures may
lead to numerous lung diseases, including fibrosis, interstitial
pneumonitis and asthma (Magaye et al., 2012). The potential
of cobalt and its compounds as carcinogenic agent was evalu-
ated by IARC in 1991.
Currently, the application and use of cobalt NPs range
from industry to medicine, but research data on its bio-
effects are limited. In addition, very little is known about the
toxicity of cobalt nanoparticles and it is assumed that its bio-
logical activity is mediated by ionic form and can be deter-
mined by evaluating its soluble compound as for other
metals but evidences showed that the biological activity of
cobalt is not exclusively mediated by ionic form dissolved in
biological media (Magaye et al., 2012).
2 S.M. Shaikh, P.V. DesaiCobalt nanoparticles are known to be genotoxic in vitro.
These NPs are internalized by leukocytes, further they interact
with DNA, leading to genotoxic effects which are seen on the
reticuloendothelial system (Magaye et al., 2012). Further it is
reported that cobalt oxide NPs enter the cells, remains con-
fined to vesicles causing production of ROS in human cell lines
(Papis et al., 2009). The in vivo study carried out in rats
revealed that cobalt nanoparticles induced malignant mes-
enchymal tumors (Magaye et al., 2012). The inhalation study
exposed to CoO aerosols with hamsters remained non-
positive (Jensen and Tu¨chsen, 1990) wherein, Syrian golden
hamsters exposed to cobalt oxide dusts showed no increase
in tumors, however, the study was faulted for poor survival
(IARC, 1991). Doses given to the mixed population of rats
over 2 years showed bronchio-alveolar proliferation at high
rates showing benign lung tumor, bronchio-alveolar carci-
noma, adenocarcinomas and bronchioalveolar adenomas
(Bucher et al., 1999). These studies indicate that cobalt
nanoparticles cause genotoxic and carcinogenic activity
in vitro and in vivo (Magaye et al., 2012). However, a few
reports indicate that NPs can reach the brain and are associ-
ated with neurodegeneration leading to Parkinson’s disease,
Huntington’s disease, Alzheimer’s disease and primary brain
tumors (Win-Shwe and Fujimaki, 2011). The exact cause of
these diseases is still unknown, but environmental factors or
pollutants, including NPs, may be a potential risk factor.
NPs can enter the body via different routes like inhalation,
dermal penetration, and ingestion, and then are distributed
to various tissues including the brain by means of systemic cir-
culation, so it becomes necessary to evaluate the toxic effects
of these NPs on the brain (Win-Shwe and Fujimaki, 2011).
Thus the review of literature indicates that most of the studies
of cobalt effects are with reference to in vitro effects showing
pseudo-tumor formation, genotoxicity on mammalian cells,
peripheral leuckocytes, BALB/3T3 mouse fibroblast cells and
macrophages whereas, the in vivo studies are only on malig-
nant mesenchymal tumors. However, there is hardly any
report of CoO NPs action on the brain as well as their reten-
tion and influence on carbohydrate metabolism of the brain.
Therefore, here an attempt is made to investigate the action
of CoO NPs on carbohydrate metabolism of the brain of mice.
Materials and methods
Nanoparticles
Cobalt oxide nanoparticles measuring average size 50 nm,
spherical in shape, black in color, 99% pure, powder in form,
without any odor, having specific surface areaP10 m2/g, den-
sity 6.1 g/cm3 and with Zeta potential 20.4 mV were obtained
from Nanoshel, Wilmington, USA (Product code NS6130-03-
380).
Preparation of nanoparticles suspensions
The NPs were suspended directly in mammalian saline (0.9%
NaCl prepared with deionized water (DI water)) in order to
coat the NPS with saline for their stabilzation and then dis-
persed by using a sonicator. A stock concentration of
100 mg/10 ml was prepared, further the dilutions were made
as per the concentration and body weight of mice. Threeconcentrations were used as 5 mg, 10 mg and 20 mg/kg body
weight (bwt) of mice. The stock and diluted suspensions of
CoO NPs were monitored for any agglomeration through
microscopic observations of sample drops of stock and suspen-
sions. The shaker bath set at 30 C helped to maintain suspen-
sion of NPs in mammalian saline.
Maintenance of animals
The healthy Mice (Mus musculus), weighing 22–32 g were
housed in polypropylene cages. The animals were maintained
at ambient laboratory conditions, with a dark and light cycle
of 12 h having free access to water and standard pellet diet
(Hindustan Lever, Bangalore, India). Ethical approval (Ref
No. 105/C-2013) was obtained from the Institutional Animal
Ethics Committee, based on the CPCSEA guidelines
(CPCSEA, 2003) and were followed throughout the study per-
iod. The animals were maintained at animal house facility in
Department of Zoology, Goa University.
Chronic treatment (30 days)
Mice were divided into 4 groups (5 mice/group) such as Con-
trols, Exp 1(5 mg/kg), Exp 2(10 mg/kg) and Exp 3 (20 mg/kg).
Based on the Ld50 values the sub lethal doses were selected for
exposure (Shaikh et al., 2015). The animals were fed orally
with nanoparticles (suspended in 0.5 ml mammalian saline
(0.9% NaCl)) for 30 days (respective dose referred above at
10 am every day). The controls received 0.5 ml of mammalian
saline. After thirty days, the animals were anaesthetized using
avertin and perfused by mammalian saline. For perfusion a
small cut was given at the right atrium and the butterfly needle
containing 20 ml of saline was slowly flushed through the left
atrium at the rate of 2 ml/min. Further the mice were decapi-
tated and the brain was immediately harvested and transferred
to an ice cold mammalian saline (0.9% NaCl). All the brain
regions viz., cerebellum, cerebral hemisphere, olfactory bulb,
medulla oblongata, hippocampus, cingulate gyrus, pons were
quickly isolated aseptically in a cold chamber set at 4 C.
Each isolated region was further cut into tiny pieces and thor-
oughly and repeatedly rinsed till all traces of blood were
removed. Further the tiny pieces were viewed under stereo
zoom microscope to ensure that there were no blood traces.
Such pieces were once again rinsed thoroughly with cold saline
and then immediately stored at 20 C until use. Assessment
of post mortem induced changes to the mice brain was per-
formed as described by Hunsucker et al. (2008) as well as by
viewing fresh frozen sections under the microscope.
Deposition of nanoparticles in the brain
After perfusion, the mice were sacrificed by decapitation
method, the brain was removed, rinsed with mammalian sal-
ine, and its cerebral cortex, cerebellum, medulla oblongata,
olfactory bulb, hippocampus, cingulate gyrus, pons were sepa-
rated carefully as mentioned above. The remaining brain tissue
was also carefully rinsed with mammalian saline and stored for
detection of CoO NPs at 4 C until use (hippocampus, cingu-
late gyrus, pons and remaining brain tissue when separated
had CoO NPs below detectable limit, so they were pooled
together for detecting CoO NPs). These brain parts along with
Table 1 Retention/deposition of cobalt oxide nanoparticles in the discrete brain regions of the mice.
Doses (CoO NPs) in
mg/kg bwt of mice
Total retention of cobalt in
the whole brain (n= 6)
Brain regions Concentration in lg/gm
dry wt. of tissue
% distribution
in the brain
5 mg/kg 49.15 lg/gm dry wt. of tissue Cerebral cortex (CC) 3.50 ± 0.208 7.12
Cerebellum (C) 9.74 ± 0.376 19.83
Medulla oblongata (MO) 12.61 ± 0.606 25.66
Olfactory bulb (OB) 19.12 ± 1.453 38.90
Hippocampus (H) ND –
Pons (P) ND –
Cingulate gyrus (CG) ND –
Other brain regions + (H, P and CG) 4.16 ± 0.007 8.47
10 mg/kg 96.67 lg/gm dry wt. of tissue Cerebral cortex 6.51 ± 0.266 6.95
Cerebellum 18.86 ± 0.368 19.50
Medulla oblongata 22.05 ± 0.818 22.82
Olfactory bulb 41.33 ± 2.185 42.75
Hippocampus ND –
Pons ND –
Cingulate gyrus ND –
Other brain regions + (H, P and CG) 7.71 ± 0.009 7.97
20 mg/kg 171.18 lg/gm dry wt. of tissue Cerebral cortex 11.01 ± 0.271 6.434
Cerebellum 34.51 ± 1.511 20.16
Medulla oblongata 37.68 ± 0.881 22.02
Olfactory bulb 74.12 ± 2.603 43.30
Hippocampus ND –
Pons ND –
Cingulate gyrus ND –
Other brain regions + (H, P and CG) 13.84 ± 0.029 8.08
Bwt – body weight, ND – non detectable, all values are expressed as mean ± SE (p  0.001).
Significance level for C, CC, MO, OB and other regions is P 6 0.001.
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60–70 C. Each dried brain tissue was digested using 30%
hydrogen peroxide followed by concentrated ultra pure nitric
acid. The digested ash was then dissolved in 0.25 N nitric acid.
Each digested sample was further diluted suitably using 0.25 N
nitric acid depending on the type and amount of tissue prior to
the analysis (Lasagna-Reeves et al., 2010) The analysis was
performed with Atomic absorption spectrophotometer; model
no-varian AA 240 FS having Air acetylene flame. Standards
were used for all the calibration curves and for calculating
metal recovery from tissues standard samples of Bovine Liver
(1577b, U.S NIST Gaithersburg, MD 20899) were used
(Shaikh et al., 2015). The% distribution/retention in the brain
was calculated by using the formula: % retention = retention
of cobalt in brain region/retention of cobalt in whole
brain  100.
Sample preparation
The brain regions (cerebellum, cerebral hemisphere, olfactory
bulb and medulla oblongata) were thawed and homogenized
in 0.32 M sucrose for enzyme assays, for pyruvate assay
0.25 M sucrose was used while for glucose and lactate assays
distilled water and 10% Trichloroacetic acid (TCA) were used
respectively. The homogenization was done in a cold chamber
set at 4 C. The respective homogenate was centrifuged at
3000 rpm for 15–20 min. The resulted supernatants were
stored in clean sterile micro centrifuge tubes at 4 C until
analysis.Metabolite assays
Glucose: It was estimated by GOD/POD method using com-
mercially available Coral crest biosystem kit (Product No
GLU1276).
Pyruvate: To a 0.1 ml of sample, 1 ml 2,4-dinitrophenylhy-
drazine (DNPH) reagent was added and incubated for 15 min
at 37 C, then 4 N NaOH was added and the mixture was kept
in room temperature for 5 mins and OD were taken at 440 nm.
Standard pyruvate curve was used to calculate the pyruvate
concentration in the samples (Therisa and Desai, 2012).
Lactate: To a 1.0 ml of sample, 1.0 ml 20% CuSO4 solu-
tion, 8 ml H2O and 1 gm of powdered Calcium hydroxide were
added and the mixture was kept at room temperature for
30 min. After centrifugation, 0.05 ml of 0.4% CuSO4 was
added to the supernatant, followed by 6 ml of Conc. H2SO4
and this was kept in a boiling water bath for 5 min. After cool-
ing, 0.1 ml of p-hydroxydiphenyl reagent was added and again
the mixture was kept at room temperature for 30 min and then
in boiling water bath for 90 s. After cooling the OD was
obtained at 560 nm. The lactate concentration was calculated
using the lactate standard curve (Therisa and Desai, 2012).
Glycogen: To 1.0 ml of sample, 5 ml of 95% ethanol was
added and kept overnight at 4 C to precipitate. Next day after
centrifugation the supernatant was discarded. To the residue
1 ml of distilled water was added and gently mixed, then
4 ml of anthrone reagent followed by Foline ciocalteau reagent
was added and the mixture was kept in a water bath
for 15 mins and the absorbance was measured at 620 nm.
Figure 1 Effect of CoO NPs on the glucose content in the brain
of mice (c – cerebellum, cc – cerebral cortex, mo – medulla
oblongata, ob – olfactory bulb, (* – P 6 0.05, ** – P 6 0.001,
# – non-significant compared to controls)).
Figure 2 Effect of CoO NPs on the pyruvate content in the brain
of mice (c – cerebellum, cc – cerebral cortex, mo – medulla
oblongata, ob – olfactory bulb, (* – P 6 0.05, ** – P 6 0.001,
# – non-significant compared to controls)).
Figure 3 Effect of CoO NPs on the lactate content in the brain
of mice (c – cerebellum, cc – cerebral cortex, mo – medulla
oblongata, ob – olfactory bulb, (* – P 6 0.05, ** – P 6 0.001,
# – non-significant compared to controls)).
Figure 4 Effect of CoO NPs on the glycogen content in the brain
of mice (c – cerebellum, cc – cerebral cortex, mo – medulla
oblongata, ob-olfactory bulb, (* – P 6 0.05, ** – P 6 0.001,
# – non-significant compared to controls)).
4 S.M. Shaikh, P.V. DesaiThe concentrations were measured using the glycogen
standard curve (Caroll et al., 1956).
Protein: Estimated using Lowry’s method (Lowry et al.,
1952).
Metabolic enzyme assays
Hexokinase (EC 2.7.1.1), glucose 6 phosphate dehydrogenase
(EC 1.1.1.49) was estimated following the protocol from Wor-
thington manual (Worthington, 1988), glucose 6 phosphatase
(EC 3.1.3.9) was assayed following a protocol of Baginsky
et al. (1974), lactate dehydrogenase (LDH) activity was
assayed using Mod. IFCC Method by using commercially
available Crest Biosystems kit (Product no-LDL1159).
Statistical analysis
All experimental data are expressed as mean ± SE. Statistical
analysis of the data was performed using Student’s t-test
(Graph pad Software, San Diego, CA) and a one-way analysis
of variance (ANOVA) using XLSTAT software. The criterion
for statistical significance was p 6 0.05 and for high signifi-
cance was p 6 0.001.Results
The procedure adopted to isolate the brain regions and prepa-
ration of samples did not promote any postmortem changes in
the brain when analyzed for cytoarchitectural changes.
Retention of nanoparticles
The maximum retention of cobalt oxide nanoparticles was seen
in cerebral cortex, cerebellum, medulla oblongata and olfac-
tory bulb (Table 1) in comparison with other brain regions.
Since the CoO NPs presence was below the detection level in
the hippocampus, cingulate gyrus, pons as well as other pooled
tissues of the brain, the changes in the carbohydrate metabo-
lism vis-a-vis metabolites and enzymes associated with
metabolites for these regions were not studied.
Metabolites
The cerebral cortex, cerebellum, medulla oblongata and olfac-
tory bulb showed a significant dose dependant increase in the
concentrations of glucose (p 6 0.001), lactate (p 6 0.05),
Figure 5 Effect of CoO NPs on the hexokinase activity in the
brain of mice (c – cerebellum, cc – cerebral cortex, mo – medulla
oblongata, ob – olfactory bulb, (* – P 6 0.05, ** – P 6 0.001,
# – non-significant compared to controls)).
Figure 6 Effect of CoO NPs on the glucose 6 phosphate
dehydrogenase activity in the brain of mice (c – cerebellum,
cc – cerebral cortex, mo – medulla oblongata, ob – olfactory bulb,
(* – P 6 0.05, ** – P 6 0.001, # – non-significant compared to
controls)).
Figure 7 Effect of CoO NPs on the glucose 6 Phosphatase
activity in the brain of mice (c – cerebellum, cc – cerebral cortex,
mo – medulla oblongata, ob – olfactory bulb, (* – P 6 0.05,
** – P 6 0.001, # – non-significant compared to controls)).
Figure 8 Effect of CoO NPs on the LDH activity in the brain of
mice (c – cerebellum, cc – cerebral cortex, mo – medulla
oblongata, ob – olfactory bulb, (* – P 6 0.05, ** – P 6 0.001, #
– non-significant compared to controls)).
Effect of CoO NPs on the carbohydrate metabolism of the brain of mice 5pyruvate (p 6 0.05) and glycogen (p 6 0.001) as compared to
control mice on exposure to CoO NPs for a period of
30 days(Figs. 1–4).
Enzyme activity
The CoO NPs appear to significantly increase the activities of
Hexokinase (p 6 0.05), glucose 6 phosphatase (p 6 0.05) and
lactate dehydrogenase (p 6 0.05) dose dependently in all the
aforementioned regions of the brain whereas glucose 6 phos-
phate dehydrogenase activities decreased significantly
(p 6 0.05) as compared to controls(Figs. 5–8).
Discussion
The effect of cobalt oxide nanoparticles on the mice in terms of
body weight and organ index, as well as distribution and reten-
tion of nanoparticles in different vital organs of body including
brain is already reported by us earlier (Shaikh et al., 2015). It is
hypothesized that environmental pollutants including
nanoparticles might be one of the reasons for neurodisorders,
but there are not many experimental evidences to substantiateit (Win-Shwe and Fujimaki, 2011). Here we report the effect of
CoO NPs on the brain. The mice fed with CoO NPs showed
the presence of these NPs in the brain indicating its retention
in it. Since the isolated brain pieces were divested of any traces
of blood, the entry of nanoparticles into the brain indicates its
entry into the neural tissue either through leaky passages of the
blood vessel’s endothelium reaching the brain or through com-
promising the blood–brain barrier. Among all the regions of
the brain tested for the presence of CoO NPs, their retention
was maximum in the cerebral cortex, cerebellum, medulla
oblongata and olfactory bulbs as these four regions are most
likely to come in contact with the nanoparticles after they cross
the blood–brain barrier and enter the brain. Therefore, the
chances of the nanoparticles retention/deposition in these
regions are high.
Carbohydrate metabolism is one of the important biochem-
ical fundamental processes that takes care of continuous sup-
ply of energy to living cells and helps in normal functioning
of the body. The mice brain exposed to CoO NPs showed a sig-
nificant dose dependant increase in glucose levels which may
promote atrophy of the brain as observed by Cherbuin et al.
(2012) and McMillen (2012) in the hippocampus and such
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bral cortex, cerebellum, medulla oblongata, olfactory bulb and
even other brain regions. The brain requires two times more
energy than the other tissue cells and due to stress created by
the retention of CoO NPs, the demand of glucose by the brain
could elevate leading to stepping up of carbohydrate metabo-
lism to mitigate glucose demand by the affected regions of the
brain. Besides the astrocytes and astroglial cells of the brain
could be contributing to an increase in glucose levels of the
brain by the breakdown of glycogen stored in them. Astrocytes
and astroglial cells are known as sources of glycogen in the
brain (Belanger et al., 2011). A further increase in the glucose
6 phosphatase activity conveys that the elevated glucose levels
are also due to formation of glucose from the non carbohy-
drate substrates via gluconeogenesis as suggested by Gerich
et al. (2001), Garrett and Charles (2002) in non neural tissues.
Also in mammalian tissues glucose 6 phosphate may return to
glucose via phosphatase action or be used in the synthesis of
glycogen or may enter into the energy yielding Embeden Mey-
erhof pathway or into the 6 phosphogluconate pathway (Irwin
and Edward, 1964). Therefore, it is likely that elevation of glu-
cose 6 phosphatase could be an attempt of the brain tissue to
divert excessive glucose 6 phosphate either to glucose or to the
process of glycogen synthesis or to divert it to energy yielding
pathways mentioned earlier to mitigate energy demand.
Hexokinase is the first enzyme involved in glucose metabo-
lism and is the major metabolic regulatory step in the brain. Its
activity is complex because more than 80% of brain hexoki-
nase is bound to the cell organelles which profoundly alter
the kinetics of the enzyme (Bigl et al., 1999). Damage to the
brain or stress to the neurons could lead to an increase in hex-
okinase activity as an attempt to step up metabolism to meet
the energy demand and increased hexokinase activity can lead
to an increase in pyruvate levels on the one hand and glycogen
on the other. Elevation of lactate dehydrogenase was also
observed in all regions of the brain under study indicating
damage caused by CoO NPs to the brain (Pulliam et al.,
1991) giving rise to an increase in lactic acid formation. The
accumulation or rise in lactate levels of the brain could be
due to elevated pyruvate levels as well as elevated LDH activ-
ity which breakdowns pyruvate to lactate. Lactate is formed in
the brain as an energy source and it is known that this lactate
triggers the release of non adrenaline by neurons to mitigate
neuronal stress (Tang et al., 2014).
Interestingly wherein all the metabolites and enzyme levels
were found to be increasing there is one enzyme that showed
completely opposite behavior i.e. glucose 6 phosphate dehy-
drogenase which showed a significant decrease in the brain
regions affecting the pentose phosphate pathway. Glucose 6
phosphate dehydrogenase has an important function in inter-
mediary metabolism since it catalyzes the very first step in
the pentose phosphate pathway and also provides reductive
potential in the form of NADPH. This enzyme is convention-
ally referred to as first and rate limiting enzyme of the pentose
phosphate pathway (Pandolfi et al., 1995). Therefore a drop in
glucose 6 phosphate dehydrogenase activities in all parts of the
brain indicate a decrease in the pentose phosphate pathway as
well as a decrease in NADPH and also a decrease in defense
against oxidative stress. This change in the activity of the
enzyme system depends upon the dose and duration of
nanoparticle exposure as well as on the susceptibility of dis-
turbed neuronal metabolism (Uttara et al., 2009). This clearlyindicates that CoO NPs cause neural stress and disturbance in
the exposed animal (Bano and Bhatt, 2010) and stepping up of
carbohydrate metabolism of the brain. However, it is not pos-
sible to know if the changes in brain biochemistry reported
here were primary toxic effects of the cobalt nanomaterials
or a secondary consequence of systemic toxicity.
Conclusion
Chronic gastrointestinal exposure of mice to CoO NPs pro-
motes its retention by the brain, especially by cerebral cortex,
cerebellum, medulla oblongata and olfactory bulb leading to
changes in the carbohydrate metabolism of the brain.Conﬂict of Interest
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